Aligos Therapeutics, Inc. Stock Split Ratio
Aligos Therapeutics, Inc. (ALGS) had Stock Split Ratio of 4.00% as of 2024-08-19, per its 10-Q filed 2024-11-06.
Financial Statements › Notes
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2024-11-06
- 2024-08-19: Stockholders' Equity Note, Stock Split, Conversion Ratio 4.00%.
- 2018-08-15: Stockholders' Equity Note, Stock Split, Conversion Ratio 90.14%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio |
|---|---|
| 2024-08-19 | 4.00% 10-Q · filed 2024-11-06 |
| 2018-08-15 | 90.14% 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |